Liver drug trial halted early: what we know about INT-787
NCT ID NCT05639543
First seen May 05, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study tested a new medicine called INT-787 for people with severe alcohol-associated hepatitis, a serious liver condition. The trial aimed to see if the drug was safe and could improve liver function. It included 67 adults who drank heavily and had jaundice. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL-ASSOCIATED HEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU Angers
Angers, 49933, France
-
Cambridge University NHS Foundation Trust
Cambridge, United Kingdom
-
Clinical Translational Research Site
Miami, Florida, 33136, United States
-
Columbia University Medical Center/New York Presbyterian Hospital
New York, New York, 10032, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hopital Beaujon
Clichy, 92118, France
-
Hopital Claude Huriez
Lille, 59037, France
-
Hopital Pitie Salpetriere
Paris, 75013, France
-
Hopital Rangueil
Toulouse, 31059, France
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Imperial College Healthcare NHS Trust
London, United Kingdom
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Mercy Medical Center
Baltimore, Maryland, 21202, United States
-
Northwell Health Center for Liver Disease and Transplantation
Manhasset, New York, 11030, United States
-
Royal Free Hospital
London, NW3 2QG, United Kingdom
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Stanford Healthcare
Palo Alto, California, 94305, United States
-
Tampa General Medical Group
Tampa, Florida, 33606, United States
-
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
-
UC Davis Medical Center
Sacramento, California, 95817, United States
-
UMass Memorial Medical Center
Worcester, Massachusetts, 01655, United States
-
University Hospitals Plymouth NHS Trust
Plymouth, United Kingdom
-
University of California, San Francisco-Fresno
Fresno, California, 93701, United States
-
University of Utah Hospital
Salt Lake City, Utah, 84132, United States
-
VCU Health Clinical Research Services Unit
Richmond, Virginia, 23298, United States
-
Vanderbilt Digestive Disease Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.